ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of growth
PR93151
LONDON, Nov. 18, 2021 /PRNewswire=KYODO JBN/ --
-- Dr. Steffen Wagner appointed as new Chief Executive Officer and Andreas
Stickler as new Chief Financial Officer
ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty
pharmaceutical company with a strategic focus on complex medicines in Europe,
today announced several changes in senior leadership roles as it enters the
next phase of its growth journey.
Photo - https://mma.prnewswire.com/media/1691859/Dr_Steffen_Wagner.jpg
Dr Steffen Wagner is to become the new Chief Executive Officer of ADVANZ
PHARMA, starting early 2022. He succeeds Graeme Duncan, who will step down from
his role and become a special advisor to the Board. Andreas Stickler will join
from Merck Healthcare as the new Chief Financial Officer, succeeding Adeel
Ahmad.
Dr Steffen Wagner is currently a member of the executive management team at
STADA Arzneimittel AG and has been responsible for the company's European
Markets division. Steffen is a medical doctor by training, has previously held
senior roles with Biogen and within the Novartis Group, and worked as a
consultant at McKinsey & Company and Bain & Company. He brings extensive
international pharma experience that will be highly valuable in supporting
ADVANZ PHARMA's continued journey. His predecessor, Graeme Duncan, has been
with ADVANZ PHARMA since 2014 and has played a significant role in building the
Company to date. He will continue working with the Board as a special advisor.
Andreas Stickler will join as the Company's new Chief Financial Officer in
January 2022. Most recently, he has been CFO of Merck Healthcare, part of Merck
KGaA, where he also served as Global Head of M&A and Business Development,
driving major strategic acquisitions. He brings a wealth of global finance,
healthcare and M&A expertise to the team. His predecessor, Adeel Ahmad, has
been with the Company since 2013 and has helped deliver major transformation
projects and built a sustainable business from which to grow.
These two key additions to the executive team of ADVANZ PHARMA are accompanied
by several other senior leadership changes. On November 1, 2021, Susanna
El-Armale joined as Chief Corporate Development Officer, following her prior
role as Chief Corporate Development Officer of Theramex and succeeding former
Chief Corporate Development Officer Guy Clark. Susanna brings broad experience
spanning both M&A and BD activities and will be a central driver of the
Company's active corporate development agenda. In January 2022, Chris Britten
will join Susanna El-Armale's team as Senior Vice President for M&A, following
his role as Head, M&A for Neuraxpharm. On October 11, Anke Niedernberg joined
as Senior Vice President and Head of the Transformation Office. She brings a
broad skillset to the leadership team, having spent time in private equity,
consulting and running major change and growth projects for Sandoz for the last
ten years.
These senior leadership changes build upon ADVANZ PHARMA's successful 2021 and
will help fuel the Company's next phase of growth. In 2021, the Company
delivered continued strong financial performance, succeeded in acquiring
additional strategic assets, commenced the European launch of a generic version
of Lanreotide and bolstered its organic pipeline with further in-licensing
deals. ADVANZ PHARMA continues building towards achieving its corporate vision
of becoming the "partner of choice" for complex specialty and hospital
medicines in Europe.
About ADVANZ PHARMA
ADVANZ PHARMA is headquartered in London and has commercial affiliates in
Europe, North America and Australia, and supply chain, regulatory and
administrative operations in India. Furthermore, ADVANZ PHARMA has an
established global network of commercial partners throughout the rest of the
world. With an agile and experienced team, including direct sales, marketing,
and medical capability across many of Europe's major markets, ADVANZ PHARMA
supplies, innovates and enhances the critical medicines patients depend on,
ensuring continued patient access and improving healthcare outcomes. ADVANZ
PHARMA has a broad expertise in several therapeutic areas with strengths in the
critical care, anti-infectives, endocrinology, cardiovascular and central
nervous system therapeutic areas, along with direct sales access in Europe,
making it an attractive partner when commercialising complex medicines,
especially in the hospital channel. To find out more, please visit our website:
Press contacts: Meral Nugent, Head of Communications, Tel: +44 7557 49 60 35,
E-mail: meral.nugent@advanzpharma.com
SOURCE: ADVANZ PHARMA Corp.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。